






Study with the several resources on Docsity
Earn points by helping other students or get them with a premium plan
Prepare for your exams
Study with the several resources on Docsity
Earn points to download
Earn points by helping other students or get them with a premium plan
Community
Ask the community for help and clear up your study doubts
Discover the best universities in your country according to Docsity users
Free resources
Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors
Material Type: Exam; Professor: Kellogg; Class: MEDICINAL CHEMISTRY & DRUG DES; Subject: Medicinal Chemistry; University: Virginia Commonwealth University; Term: Unknown 1989;
Typology: Exams
Limited-time offer
Uploaded on 02/10/2009
5
(1)10 documents
1 / 11
This page cannot be seen from the preview
Don't miss anything!
On special offer
Name:____________________________ Pledge: _______________________
(All questions are 2.25 points unless otherwise stated.)
G.E. Kellogg
A) Synthetic and Biophysical Organic Chemistry. B) Structure Based Drug Design. C) QSAR. D) High Throughput Screening (finding a needle in a hay stack). E) Isosteric Replacement.
A) Quality Structure Analysis for Receptors B) Quiet Structure Analysis by Researchers C) Quantitative Structure-Activity Relationships D) Quick Structure Analysis Reasoning E) None of the above.
TRUE FALSE
A) μ-spiral and β-cone B) α-box and ε-zigzag C) α-helix and β-sheet D) π-sphere and β-helix E) α-sheet and β-helix
Y.A. Zhang
A) The basic structural component of membrane system is phospholipid molecules and their chemical structure decides the character of the membrane architecture. B) While some drugs can pass through the membrane by passive diffusion, others may be carried into the cells by carrier protein via active transport. Both processes need energy compensation. C) After absorption some drug molecules may act on the target protein while others may be metabolized even before reaching the site of action. D) After being absorbed, some drug molecules will bind to plasma proteins non-specifically and will not be available for pharmaco-logical activity until they are released.
N
CH 2 COOH
CH 3
H 3 CO
O
Cl
Indomethacin
A) 0 - 2 D) 10 - 12 B) 2 - 4 E) > 14 C) 7 - 9
A) Mouth (pH 6-7) D) Colon (pH 8) B) Stomach (pH 1-3) E) Not absorbed if given orally C) Small Intestine (pH 7-7.5)
A) transporter B) signal transduction C) somatodendritic (cell body) autoreceptors D) terminal autoreceptors
A) an agonist B) a releasing agent C) an indirect agonist D) a negative allosteric modulator E) a positive allosteric modulator
14-15. Receptors can be grouped into two major superfamilies: G-protein coupled receptors and ligand-gated ion channel (LGIC) receptors. Whereas the former are composed of seven transmembrane-spanning helicies made up of various amino acid residues, the latter are quite different. For example, LGIC nicotinic acetylcholinergic receptors and 5-HT3 serotonin receptor consists of (14) _________ subunit(s), each consisting of (15) _______ transmembrane- spaning helicie(s). Complete the last sentence by selecting answers from the list below:
A) one D) four B) two E) five C) three
A) G-protein coupled receptors B) ligand-gated ion channel receptors
A) benzodiazepines C) phenothiazines B) butyrophenones D) thioxanthenes
A) Anticholinergic activity B) Antihistaminic activity C) Extrapyramidal stimulation D) Answers A), B) and C) are correct E) Answers A) and B), but not C) is correct.
A) an electron donating group at the ring 2-position B) a three atom chain separating the ring from the terminal amine C) a basic tertiary amine D) ability to interact with dopamine receptors
A) alkylation D) esterification B) acylation E) aminolysis C) hydrolysis
A) lack of dopamine in functionally important synapses in the brain B) excess dopamine in functionally important synapses in the brain C) lack of serotonin in functionally important synapses in the brain D) excess serotonin in functionally important synapses in the brain
A) blockade of dopamine reuptake B) blockade of postsynaptic dopamine receptors C) release of presynaptic dopamine D) interaction with somatodendritic receptors on DA neurons E) interaction with terminal autoreceptors of DA neurons
R. Young
A) MDMA B) Methylenedioxymethamphetamine C) Cathinone D) DOM E) A) and B)
TRUE FALSE
A) The drug discrimination procedure provides only quantitative information about a compound. B) Only stimulants and hallucinogens have been used in drug discrimination studies. C) Results from some drug discrimination studies have been shown to parallel(correlate) with human studies. D) A) and B) only E) All of the above.
A) DOM can function as a discriminative stimulus B) R(-)-DOM is less potent than S(+)-DOM C) DOM generalization occurs to amphetamine D) All of these E) A) and B) only
A) “natural amphetamine” B) “STP” C) “Khat” D) A) and C) E) None of these
A) Discrimination B) Antagonism C) Stereoselectivity D) Shaping E) None of these
B.E. Windle
A) Developing a hypothesis B) Designing an experiment C) Collecting large amounts of data D) Making conclusions from experiments E). Analyzing large amounts of data
A) Developing a hypothesis B) Designing an experiment C) Collecting large amounts of data D) Making conclusions from experiments E) Analyzing large amounts of data
A) Collecting data B) Developing a hypothesis C) Developing a model D) Testing a hypothesis E) Making conclusions
A) Transport of the drug B) Metabolism of the drug C) drug mutates cellular DNA D) Interaction with the drug target
A) V = 0.5 L; CL = 0.09 L/h B) V = 20 L; CL = 3.46 L/h C) V = 10 L; CL = 0.173 L/h D) V = 10 L; CL = 1.73 L/h
A) The time it takes for AUC to increase by ½. B) The time it takes for AUC to decrease by ½. C) The time it takes for the elimination rate constant to decrease by ½. D) The time it takes for drug concentrations to decrease by ½.
A) Volume of distribution is how much of a drug is administered intravenously B) Bioavailability is approximately 80% after intravenous administration of a drug C) Lipophilic drugs are usually eliminated by metabolism D) Renal clearance involves Phase I enzymes
W.H. Soine
A) It is often a structural modification of a controlled or regulated drug. B) It is usually not illegal. C) It may retain pharmacological activity similar to the regulated drug. D) The toxicity and doses are usually unknown. E) All of the above.
A) Unknown or unanticipated pharmacological effects. B) Difficulty formulating the drug at the appropriate dose. C) Small difference between therapeutic effect and toxicity. D) Drug may be impure. E) All of the above.
A) Feces in marihuana B) Cyanide in phencyclidine C) Mercury in methamphetamine D) Quinidine instead of quinine to “cut” heroin E) All of the above
A) The designer drug is safer. B) Toxic effects from the common drug is less likely. C) There is a small difference between therapeutic effect and toxicity for the designer drug compared with the common drug. D) There is no difference between therapeutic effect and toxicity for the designer drug compared with the common drug. E) None of the above.
A) Heroin addition B) Overdoses due to an increase in activity C) Food poisoning D) Parkinson’s disease E) Stroke and cardiac arrest
A) A material with unknown or unanticipated pharmacological effects. B) A new compound that will soon replace heroin on the “street”. C) A highly toxic drug. D) An extremely pure form of heroin. E) All of the above.